Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2010 | Review

Current implications of cyclophilins in human cancers

Authors: Jinhwa Lee, Sung Soo Kim

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Excerpt

Cyclophilins (Cyps), the intracellular receptor for immunosuppressant cyclosporine A (CsA), play important cellular roles through activities of peptidyl-prolyl cis-trans isomerase (PPIase) and chaperones. Cyps are structurally conserved and found in both prokaryotic and eukaryotic organisms, including humans which contain 16 Cyp isoforms. Although human Cyps were identified about 25 years ago, their physiological and pathological roles have only been the focus of attention recently because of their possible involvement in diseases and ailments such as HIV infection, hepatitis B and C viral infection, atherosclerosis, ER stress-related diseases and neurodegenerative diseases, etc. There are reports for upregulated Cyps in many human cancers and there are also strong correlations found between Cyps overexpression and malignant transformation. This review discusses the important and diverse roles of Cyps overexpression in human cancers. Understanding biological functions of Cyps will eventually lead to improved strategies for cancer treatment and prevention. …

Fischer G, Tradler T, Zarnt T: The mode of action of peptidyl prolyl cis/trans isomerase in vivo: Binding vs catalysis. FEBS Lett. 1998, 426: 17-20. 10.1016/S0014-5793(98)00242-7.CrossRef

Schmid FX: Protein folding. Prolyl isomerase join the fold. Curr Biol. 1995, 5: 993-994. 10.1016/S0960-9822(95)00197-7.CrossRef

Schreiber SL: Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell. 1992, 70: 365-368. 10.1016/0092-8674(92)90158-9.CrossRef

Göthel SF, Marahiel MA: Peptidyl-prolyl cis-trans isomerase, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci. 1999, 55: 423-436. 10.1007/s000180050299.CrossRef

Hunter T: Prolyl isomerase and nuclear function. Cell. 1998, 92: 141-143. 10.1016/S0092-8674(00)80906-X.CrossRef

Rutherford SL, Zuker CS: Protein folding and the regulation of signaling pathways. Cell. 1994, 79: 1129-1132. 10.1016/0092-8674(94)90003-5.CrossRef

Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell. 1991, 66: 807-815. 10.1016/0092-8674(91)90124-H.CrossRef

Galat A: Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity targets functions. Curr Top Med Chem. 2003, 3: 1315-1347. 10.2174/1568026033451862.CrossRef

Anderson SK, Gallinger S, Roder J, Frey J, Young HA, Ortaldo JR: A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci USA. 1993, 90: 542-546. 10.1073/pnas.90.2.542.CrossRef

10.

Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD: Cyclophilin A modelates the sensitivity of HIV-1 to host restriction factors. Nat Med. 2003, 9: 1138-1143. 10.1038/nm910.CrossRef

11.

Wohlfarth C, Efferth T: Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin. 2009, 30 (1): 25-30. 10.1038/aps.2008.5.CrossRef

12.

Satoh K, Nigro P, Berk BC: Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin a. Antioxid Redox Signal. 2010, 1:12 (5): 675-682. 10.1089/ars.2009.2875.CrossRef

13.

Hong F, Lee J, Song JW, Lee SJ, Ahn H, Cho JJ, Ha J, Kim SS: Cyclosporine A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine A-induced cytotoxicity. FASEB J. 2002, 16: 1633-1635.

14.

Wiederrecht G, Lam E, Hung S, Martin M, Sigal N: The mechanism of action of FK- 506 and cyclosporine A. Ann NY Acad Sci. 1993, 696: 9-19. 10.1111/j.1749-6632.1993.tb17137.x.CrossRef

15.

Corton JC, Moreno ES, Merritt A, Bocos C, Cattley RC: Cloning genes responsive to a hepatocarcinogenic peroxisome proliferator chemical reveals novel targets of regulation. Cancer Lett. 1998, 134: 61-71. 10.1016/S0304-3835(98)00241-9.CrossRef

16.

Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH, Jung G: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun. 2002, 291: 1031-1037. 10.1006/bbrc.2002.6547.CrossRef

17.

Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004, 46: 313-323. 10.1016/j.lungcan.2004.05.013.CrossRef

18.

Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, Patz EF: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 2005, 65: 8853-8860. 10.1158/0008-5472.CAN-05-1219.CrossRef

19.

Yang H, Chen J, Yang J, Qiao S, Zhao S, Yu L: Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun. 2007, 361: 763-767. 10.1016/j.bbrc.2007.07.085.CrossRef

20.

Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003, 63: 1652-1656.

21.

Cecconi D, Astner H, Donadelli M, Palmieri M, Missiaglia E, Hamdan M, Scarpa A, Righetti PG: Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. Electrophoresis. 2003, 24: 4291-4303. 10.1002/elps.200305724.CrossRef

22.

Shen J, Person MD, Zhu J, Abbruzzese JL, Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64: 9018-9026. 10.1158/0008-5472.CAN-04-3262.CrossRef

23.

Li M, Wang H, Li F, Fisher WE, Chen C, Yao Q: Effect of cyclophilin A on gene expression in human pancreatic cancer cells. Am J Surg. 2005, 190: 739-745. 10.1016/j.amjsurg.2005.07.013.CrossRef

24.

Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, Yao Q: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer. 2006, 106: 2284-2294. 10.1002/cncr.21862.CrossRef

25.

Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I, Nakamura K: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol. 2007, 30: 849-855.

26.

Zheng J, Koblinski JE, Dutson LV, Feeney YB, Clevenger CV: Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res. 2008, 68: 7769-7778. 10.1158/0008-5472.CAN-08-0639.CrossRef

27.

Hathout Y, Riordan K, Gehrmann M, Fenselau C: Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. J Proteome Res. 2002, 1: 435-442. 10.1021/pr020006i.CrossRef

28.

Melle C, Osterloh D, Ernst G, Schimmel B, Bleul A, von Eggeling F: Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med. 2005, 16: 11-17.

29.

Lou J, Fatima N, Xiao Z, Stauffer S, Smythers G, Greenwald P, Ali IU: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1598-1606. 10.1158/1055-9965.EPI-06-0216.CrossRef

30.

Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, Wong MC, Lam MY, Au TC, Chan WH, Cheuk W, Chan AT: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep. 2008, 20: 89-98.

31.

Chen J, He QY, Yuen AP, Chiu JF: Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics. 2004, 24: 2465-2475. 10.1002/pmic.200300762.CrossRef

32.

Qi YJ, He QY, Ma YF, Du YW, Liu GC, Li YJ, Tsao GS, Ngai SM, Chiu JF: Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem. 2008, 104: 1625-1635. 10.1002/jcb.21727.CrossRef

33.

Al-Ghoul M, Brück TB, Lauer-Fields JL, Asirvatham VS, Zapata C, Kerr RG, Fields GB: Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res. 2008, 27: 4107-4118. 10.1021/pr800174k.CrossRef

34.

Han X, Yoon SH, Ding Y, Choi TG, Choi WJ, Kim YH, Kim YJ, Huh YB, Ha J, Kim SS: Cyclosproin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep. 2010, 23: 1053-1062. 10.3892/or_00000816.CrossRef

35.

Weisinger G, Gavish M, Mazurika C, Zinder O: Transcription of actin, cyclophilin and glyceraldehyde phosphate dehydrogenase genes: Tissue- and treatment-specificity. Biochimica et Biophysica Acta - Gene Structure and Expression. 1999, 1446 (3): 225-232. 10.1016/S0167-4781(99)00091-3.CrossRef

36.

Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, Kim SS: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 2007, 67: 3654-3662. 10.1158/0008-5472.CAN-06-1759.CrossRef

37.

Gu S, Liu Z, Pan S, Jiang Z, Lu H, Amit O, Bradbury EM, Hu C A, Chen X: Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol Cell Proteomics. 2004, 3: 998-1008. 10.1074/mcp.M400033-MCP200.CrossRef

38.

Yu X, Harris SL, Levine AJ: The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66: 4795-4801. 10.1158/0008-5472.CAN-05-4579.CrossRef

39.

Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X, Crook T, Del Sal G: The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol. 2007, 14: 912-920. 10.1038/nsmb1306.CrossRef

40.

Chaurand P, Rahman MA, Hunt T, Mobley JA, Gu G, Latham JC, Caprioli RM, Kasper S: Monitoring mouse prostate development by profiling and imaging mass spectrometry. Molecular & Cellular Proteomics. 2008, 7: 411-423.CrossRef

41.

Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K: The human tumor cell derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995, 55: 434-439.

42.

Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M: Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem. 2005, 280: 17013-17019. 10.1074/jbc.M412851200.CrossRef

43.

Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis. 2006, 25: 54-64. 10.1016/j.nbd.2006.08.012.CrossRef

44.

45.

Kim J, Choi TG, Ding Y, Kim Y, Ha KS, Lee KH, Kang I, Ha J, Kaufman RJ, Lee J, Choe W, Kim SS: Overexpressed cyclophilin B suppresses apoptosis associated with ROS and Ca2+ homeostasis after ER stress. J Cell Sci. 2008, 121: 3636-364. 10.1242/jcs.028654.CrossRef

46.

Fang F, Flegler AJ, Du P, Lin S, Clevenger CV: Expression of cyclophilin B is associated progression and regulation with malignant of genes implicated in pathogenesis of breast cancer. Am J Pathol. 2009, 174 (1): 297-308. 10.2353/ajpath.2009.080753.CrossRef

47.

Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumorspecific CTLs. J Immunol. 1999, 163: 4994-5004.

48.

Mi Z, Oliver T, Guo H, Gao C, Kuo PC: Thrombin-cleaved COOH-terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res. 2007, 67: 4088-4097. 10.1158/0008-5472.CAN-06-4066.CrossRef

49.

Marzo I, Brenner C, Zamzami N, Susin SA, Beutner G, Brdiczka D, Rémy R, Xie ZH, Reed JC, Kroemer G: The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2- related proteins. J Exp Med. 1998, 187: 1261-1271. 10.1084/jem.187.8.1261.CrossRef

50.

Lin DT, Lechleiter JD: Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. J Biol Chem. 2002, 277: 31134-31141. 10.1074/jbc.M112035200.CrossRef

51.

Halestrap A: Biochemistry: A pore way to die. Nature. 2005, 434: 578-579. 10.1038/434578a.CrossRef

52.

Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, Crompton M: Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress. Eur Biochem J. 1996, 238: 166-172. 10.1111/j.1432-1033.1996.0166q.x.CrossRef

53.

Eliseev RA, Malecki J, Lester T, Zhang Y, Humphrey J, Gunter TE: Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect. J Biol Chem. 2009, 284: 9692-9699. 10.1074/jbc.M808750200.CrossRef

54.

Ward BK, Mark PJ, Ingram DM, Minchin RF, Ratajczak T: Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat. 1999, 58: 267-280. 10.1023/A:1006390804515.CrossRef

55.

Mark PJ, Ward BK, Kumar P, Lahooti H, Minchin RF, Ratajczak T: Human cyclophilin 40 is a heat shock protein that exhibits altered intracellular localization following heat shock. Cell Stress Chaperones. 2001, 6: 59-70. 10.1379/1466-1268(2001)006<0059:HCIAHS>2.0.CO;2.CrossRef

56.

Ward BK, Kumar P, Turbett GR, Edmondston JE, Papadimitriou JM, Laing NG, Ingram DM, Minchin RF, Ratajczak T: Allelic loss of cyclophilin 40, an estrogen receptor-associated immunophilin, in breast carcinomas. J Cancer Res Clin Oncol. 2001, 127: 109-115. 10.1007/s004320000182.CrossRef

Title: Current implications of cyclophilins in human cancers
Authors: Jinhwa Lee
Sung Soo Kim
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-29-97

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion

Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity

RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

The E-cadherin repressor slug and progression of human extrahepatic hilar cholangiocarcinoma

Up-regulation of fas reverses cisplatin resistance of human small cell lung cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer